Drug Trial Radar · NCT05430373
GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
31
Planned (sponsor's estimate)
Start
May 23, 2022
Primary completion
Sep 25, 2025
Study completion Dec 30, 2026
Sponsor
- Lead sponsor
- Grit BiotechnologyIndustry
- Sponsor type
- Industry
- First posted
- Jun 24, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, single-arm phase I clinical trial.The study process was divided into: screening period, sampling and production period, lymphodepleting chemotherapy period, treatment and observation period, and follow-up period. The study is designed to enroll 20-31 subjects, with 14-20 participants expected to be evaluable, in an "autologous tumor-infiltrating lymphocyte therapy" regimen that includes: 1. Clear lymphatic pretreatment (FC regimen: cyclophosphamide + fludarabine). 2. GT101 infusion. 3. post-infusion treatment (interleukin-2 intravenous push).
Conditions
- Solid Tumors, Adult
Interventions
GT101Biological
Autologous tumor infiltrating lymphocyte injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety Profile Measured by Grade ≥3 TEAEsTime frame: From infusion to Week 24
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
The fifth medical center of the General Hospital of the Chinese people's Liberation Army
Beijing, Beijing Municipality, China
Chongqing University Cancer Center
Chongqing, Chongqing Municipality, China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
West China School of Medicine/West China Hospital of Sichuan University
Chengdu, Sichuan, China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.